Focused Ultrasound Neuromodulation

📖 Wiki Page

technology1070 wordssynced 2026-04-02

Overview

flowchart TD technologies_focused_ultrasoun["Focused Ultrasound Neuromodulation"] style technologies_focused_ultrasoun fill:#4fc3f7,stroke:#333,color:#000 technologies_focused_0["Mechanism of Action"] technologies_focused_ultrasoun -->|"includes"| technologies_focused_0 style technologies_focused_0 fill:#81c784,stroke:#333,color:#000 technologies_focused_1["Biophysical Mechanisms"] technologies_focused_ultrasoun -->|"includes"| technologies_focused_1 style technologies_focused_1 fill:#ef5350,stroke:#333,color:#000 technologies_focused_2["Neural Pathway Effects"] technologies_focused_ultrasoun -->|"includes"| technologies_focused_2 style technologies_focused_2 fill:#ffd54f,stroke:#333,color:#000 technologies_focused_3["Clinical Applications in Neurodegeneration"] technologies_focused_ultrasoun -->|"includes"| technologies_focused_3 style technologies_focused_3 fill:#ce93d8,stroke:#333,color:#000 technologies_focused_4["Parkinsons Disease"] technologies_focused_ultrasoun -->|"includes"| technologies_focused_4 style technologies_focused_4 fill:#4fc3f7,stroke:#333,color:#000 technologies_focused_5["Alzheimers Disease"] technologies_focused_ultrasoun -->|"includes"| technologies_focused_5 style technologies_focused_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

[Focused Ultrasound Neuromodulation](/therapeutics/focused-ultrasound-neuromodulation) (FUS) is a non-invasive technique that uses focused acoustic energy to modulate neural activity in specific [brain regions](/brain-regions/). Unlike surgical interventions, FUS achieves targeted neuromodulation without craniotomy or implanted devices, making it particularly attractive for treating [neurodegenerative diseases](/diseases/neurodegenerative-disease) where patient safety and minimally invasive approaches are paramount.[@tyler2018]

The technology works by delivering precisely focused ultrasound waves to a specific brain target, where mechanical pressure waves interact with neuronal membranes and can either excite or inhibit neural firing depending on the ultrasound parameters (frequency, intensity, duration).[@maher2019]

Mechanism of Action

Biophysical Mechanisms

FUS modulates neural activity through several biophysical mechanisms:

Mechanical Effects: Ultrasound pressure waves create mechanical deformation of neuronal membranes, affecting [ion channel](/proteins/ion-channels) function and neuronal excitability.

Cavitation: Inertial cavitation (microbubble formation and collapse) can enhance neuromodulation effects by creating localized mechanical stress.

Thermal Effects: At higher intensities, focused ultrasound can produce localized heating, though low-intensity FUS (LIFU) avoids significant thermal effects.

Blood-Brain Barrier Modulation: FUS can temporarily open the [blood-brain barrier](/mechanisms/blood-brain-barrier-dysfunction), potentially enhancing drug delivery for neurodegenerative disease treatment.[@burgess2021]

Neural Pathway Effects

Excitatory Effects: Low-intensity FUS at certain frequencies can increase neuronal firing rates, useful for activating underactive circuits in [Parkinson's disease](/diseases/parkinsons-disease).
Inhibitory Effects: Higher intensity or specific parameter combinations can suppress neural activity, potentially for targeting hyperactive circuits in conditions like [essential tremor](/diseases/essential-tremor).
Network Modulation: FUS affects entire neural networks, not just single neurons, making it suitable for addressing circuit-level dysfunction in [neurodegenerative diseases](/diseases/neurodegenerative-disease).[@pouget2020]

Clinical Applications in Neurodegeneration

Parkinson's Disease

FUS shows particular promise for PD treatment:

Tremor Suppression: [Focused ultrasound thalamotomy](/therapeutics/focused-ultrasound-thalamotomy) (Exablate Neuro, Insightec) is FDA-approved for treating [essential tremor](/diseases/essential-tremor) and has shown efficacy for PD tremor.[@food2022]
Motor Function Improvement: Targets include the [thalamus](/brain-regions/thalamus), [subthalamic nucleus](/cell-types/subthalamic-nucleus), and [globus pallidus internus](/brain-regions/globus-pallidus).
Non-Motor Symptoms: Research explores FUS for PD-associated dysautonomia and cognitive symptoms.

Alzheimer's Disease

FUS applications in AD include:

Amyloid Clearance: Animal studies show FUS can enhance clearance of [amyloid-beta plaques](/mechanisms/amyloid-beta-aggregation) by temporarily opening the [blood-brain barrier](/mechanisms/blood-brain-barrier-dysfunction).[@leinenga2015]
Memory Enhancement: [Hippocampal](/brain-regions/hippocampus) FUS targeting may enhance memory consolidation and retrieval.
Neuroprotection: FUS may promote [neurotrophic factor](/proteins/bdnf-protein) release and reduce [neuroinflammation](/mechanisms/neuroinflammation).

Amyotrophic Lateral Sclerosis (ALS)

Emerging applications include:

Motor cortex targeting to preserve [motor neuron](/cell-types/motor-neurons) function
Bulbar function preservation for speech and swallowing
[Autonomic nervous system](/mechanisms/autonomic-nervous-system) modulation for respiratory support

Multiple System Atrophy (MSA)

Targeting of specific [brainstem nuclei](/brain-regions/brainstem) affected in [MSA](/diseases/multiple-system-atrophy)
[Autonomic function modulation](/therapeutics/autonomic-dysfunction-therapy)

Technology Platforms

Current FDA-Approved Systems

| Company | Device | Approval | Target |
|---------|--------|----------|--------|
| Insightec | Exablate Neuro | FDA (2020) | Thalamus for essential tremor |
| Insightec | Exablate Neuro | FDA (2022) | PD tremor |
| Theraclion | EchoMagic | CE Mark | Various neurological targets |

Research Systems

Harvard/Boston University LIFU System: Low-intensity focused ultrasound for neuromodulation research
Philips HIFU: Integrated MRI-guided focused ultrasound
Image Guided Therapy (IGT): MRI-guided FUS platform

Key Parameters

| Parameter | Typical Range | Effect |
|-----------|---------------|--------|
| Frequency | 0.2–2.0 MHz | Lower = deeper penetration |
| Intensity | 0.1–3.0 W/cm² | Higher = stronger modulation |
| Duration | 0.5–30 seconds | Longer = more sustained effects |
| Target Size | 2–10 mm diameter | Precision of focus |

Clinical Evidence

Parkinson's Disease

Phase III Trial (Insightec): 72% improvement in tremor scores at 12 months[@elias2016]
Open-Label Studies: Sustained benefit observed up to 3 years post-treatment
Comparison to DBS: Less invasive but with less precise targeting than implanted electrodes

Multiple Studies: 50-80% reduction in tremor amplitude
Bilateral Treatment: Possible with sequential procedures
Cognitive Effects: No significant cognitive decline observed

Alzheimer's Disease (Preclinical/Early Clinical)

Animal Models: Reduced amyloid plaques and improved memory in mouse models[@jordo2019]
Phase I Trials: Safety established in early human studies
Ongoing Trials: Multiple Phase I/II trials for AD (NCT identifier pending)

Advantages and Limitations

Advantages

Non-Invasive: No surgery, no [implanted hardware](/therapeutics/implantable-neurotechnology)

Precise Targeting: [MRI](/technologies/mri-neuroimaging) guidance allows sub-millimeter accuracy

Adjustable Effects: Parameters can be tuned in real-time

Reversible: Effects can be adjusted or allowed to wear off

No Infection Risk: Unlike [implanted devices](/technologies/brain-computer-interface), no risk of hardware infection

Outpatient Procedure: Can be performed without hospitalization

Limitations

Limited Depth: Ultrasonic waves have limited penetration depth

Skull Attenuation: Bone absorbs significant ultrasound energy

Single Target: Difficult to modulate multiple [brain regions](/brain-regions/) simultaneously

Variable Response: Individual response rates vary significantly

Insurance Coverage: Limited coverage for some indications

Access: Available only at specialized centers with MRI-FUS equipment

Research Frontiers

Emerging Applications

Blood-Brain Barrier Opening: Enhancing [drug delivery](/therapeutics/drug-delivery-neurodegeneration) for neurological diseases
Blood-Brain Barrier Opening for Immunotherapy: Enabling antibody-based treatments for [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease)
Opening BBB for [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration): Combining FUS with viral vector delivery
Closed-Loop Systems: Real-time neural monitoring with FUS feedback
Sonogenetics: Using ultrasound to activate genetically modified [neurons](/cell-types/neurons)
Network Mapping: Using FUS to map functional brain connectivity

Ongoing Clinical Trials

NCT05019087: FUS for [Parkinson's disease](/diseases/parkinsons-disease) motor symptoms
NCT05223960: FUS for [Alzheimer's disease](/diseases/alzheimers-disease) cognitive enhancement
NCT05324068: FUS combined with [anti-amyloid immunotherapy](/therapeutics/immunotherapy-alzheimers)

Cross-References

[Deep Brain Stimulation](/treatments/deep-brain-stimulation) — Surgical alternative
[Adaptive DBS](/therapeutics/adaptive-deep-brain-stimulation) — Closed-loop neuromodulation
[Blood-Brain Barrier](/mechanisms/blood-brain-barrier-dysfunction) — FUS-mediated opening
[Parkinson's Disease](/diseases/parkinsons-disease) — Clinical applications
[Alzheimer's Disease](/diseases/alzheimers-disease) — Research applications
[Neuroplasticity](/mechanisms/neuroplasticity) — FUS-enhanced plasticity
[Motor Neuron Pathways](/cell-types/motor-neurons) — Neural circuits affected

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Tyler et al., (2018). Focused ultrasound: A novel tool for neuromodulation. Nature Reviews Neurology (2018)](https://doi.org/10.1038/s41582-018-0028-5)

[Maher et al., (2019). Ultrasound neuromodulation: A review of current status and future directions. Brain Stimulation (2019)](https://doi.org/10.1016/j.brs.2019.04.012)

[Burgess et al., (2021). Blood-brain barrier opening with focused ultrasound for drug delivery. Nature Reviews Drug Discovery (2021)](https://doi.org/10.1038/s41573-021-00256-8)

[Pouget et al., (2020). Emerging opportunities and challenges for focused ultrasound in neurology. Brain (2020)](https://doi.org/10.1093/brain/awaa144)

Unknown, Food and Drug Administration (2022). Exablate Neuro: FDA Approval Summary (2022)

[Leinenga et al., (2015). Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Science Translational Medicine (2015)](https://doi.org/10.1126/scitranslmed.aab1560)

[Elias et al., (2016). A randomized trial of focused ultrasound thalamotomy for essential tremor. New England Journal of Medicine (2016)](https://doi.org/10.1056/NEJMoa1600159)

[Jordão et al., (2019). Antibody delivery and immune cell activation by focused ultrasound enhances amyloid clearance in Alzheimer's disease models. Nature Communications (2019)](https://doi.org/10.1038/s41467-019-09518-9)

Pathway Diagram

The following diagram shows the key molecular relationships involving Focused Ultrasound Neuromodulation discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Focused Ultrasound Neuromodulation

Overview

Overview

Mechanism of Action

Biophysical Mechanisms

Neural Pathway Effects

Clinical Applications in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Technology Platforms

Current FDA-Approved Systems

Research Systems

Key Parameters

Clinical Evidence

Parkinson's Disease

Essential Tremor (Parkinson's-related)

Alzheimer's Disease (Preclinical/Early Clinical)

Advantages and Limitations

Advantages

Limitations

Research Frontiers

Emerging Applications

Ongoing Clinical Trials

Cross-References

See Also

External Links

References

Pathway Diagram